Endocrinologists should discuss thyroid function and other endocrine conditions with an ophthalmologist when treating thyroid eye disease. New treatments are being assessed in clinical trials.

“Over the past few years, with the advent of pharmaceutical therapy for thyroid eye disease, it’s a little more in the forefront. With the marketing and ads on TV, it’s become more commonly ...

Veligrotug improved proptosis, diplopia and clinical activity score in patients with active or chronic thyroid eye disease at 15 weeks. An FDA approval decision is expected in the second half of 2026.

An anti-inflammatory eating plan, such as a Mediterranean diet, can be beneficial when you’re dealing with thyroid eye disease. This diet focuses on eating whole foods and avoiding processed ...

In other recent news, Viridian Therapeutics has received Breakthrough Therapy Designation from the FDA for veligrotug, a treatment for thyroid eye disease (TED). This designation follows the drug ...

Thyroid eye disease (TED) is complicated, with symptoms that can vary from person to person. It’s not widely understood — even by healthcare providers in some cases. Research indicates that it ...

Although there’s no cure for thyroid eye disease (TED), effective treatments and lifestyle changes can help you manage symptoms, such as double vision, eye pain, and dry, irritated eyes.

Veligrotug is an intravenously (IV) delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody in phase 3 development for thyroid eye disease, with the potential to be the IV ...

in patients with active thyroid eye disease (TED). TED is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eye. The THRIVE phase 3 ...

Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly ...

Research has associated cannabis use with an increased incidence of thyroid eye disease (TED) in patients with autoimmune hyperthyroidism, particularly within the first year of diagnosis.